Last reviewed · How we verify
PEG-ascorbate 2L
PEG-ascorbate 2L is a polyethylene glycol-conjugated form of vitamin C designed to improve systemic delivery and bioavailability of ascorbate for antioxidant and potential anti-cancer effects.
PEG-ascorbate 2L is a polyethylene glycol-conjugated form of vitamin C designed to improve systemic delivery and bioavailability of ascorbate for antioxidant and potential anti-cancer effects. Used for Cancer (specific indication under investigation in phase 3 trial).
At a glance
| Generic name | PEG-ascorbate 2L |
|---|---|
| Also known as | Moviprep® |
| Sponsor | Parc de Salut Mar |
| Drug class | Antioxidant/Vitamin derivative |
| Target | Ascorbate receptor (SVCT1/SVCT2) and general oxidative stress pathways |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By conjugating ascorbic acid (vitamin C) to polyethylene glycol, the drug aims to enhance pharmacokinetic properties, improve cellular uptake, and maintain higher circulating levels of ascorbate. This may enable ascorbate to exert pro-oxidant effects at high concentrations in cancer cells while providing antioxidant protection to normal tissues, potentially enhancing therapeutic efficacy in oncology applications.
Approved indications
- Cancer (specific indication under investigation in phase 3 trial)
Common side effects
- Gastrointestinal disturbances
- Infusion-related reactions
- Hyperglycemia
Key clinical trials
- Impact of Chewing Gum on Bowel Preparation in Patients Undergoing Colonoscopy (NA)
- Efficacy and Safety of mAnnitol in Bowel Preparation During Elective Colonoscopy and Comparison With Moviprep® (PHASE2, PHASE3)
- Effect of Low-volume (1L) vs Intermediate-volume (2L) Bowel Preparation on Cost-effectiveness and Quality of Life (NA)
- 1L-PEG-Asc Solution for Bowel Preparation in an "Open Access" Colonoscopy Booking System: Evaluation of Adverse Events
- Comparison for Efficacy and Safety of Bowel Preparation Between Oral Sulfate Table and 2L-polyethylene Glycol/Ascorbate in Elderly (PHASE4)
- Colon Cleansing Efficacy With 1L vs. 2L vs. 4L-PEG for Colonoscopy Among Inpatients (PHASE4)
- Comparison of Different Low Volume Solutions Prior to Colonoscopy (PHASE4)
- The Impact of Additional Oral Preparation on the Quality of Bowel Preparation for Colonoscopy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEG-ascorbate 2L CI brief — competitive landscape report
- PEG-ascorbate 2L updates RSS · CI watch RSS
- Parc de Salut Mar portfolio CI